Association between immune-related adverse events spectrum and efficacy of pembrolizumab in patients with advanced urothelial cancer

Association between immune-related adverse events spectrum and efficacy of pembrolizumab in patients with advanced urothelial cancer

Bibliographic Details
Main Authors: T. Tamiya, T. Kijima, H. Tanaka, S. Yoshida, M. Yokoyama, J. Ishioka, Y. Matsuoka, N. Numao, Y. Sakai, K. Saito, N. Matsubara, T. Yuasa, H. Masuda, J. Yonese, Y. Kageyama, Y. Fujii
Format: Article
Language:English
Published: Elsevier 2020-07-01
Series:European Urology Open Science
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168320336545

Internet

http://www.sciencedirect.com/science/article/pii/S2666168320336545

Similar Items